Navigation Links
Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research
Date:12/9/2009

SHANGHAI, Dec. 9 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd. (ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, today announced that ChemPartner scientists are pleased to have been involved in recent groundbreaking cancer research from Agios Pharmaceuticals through the companies' ongoing partnership. This breakthrough discovery by Agios scientists was recently published online on November 22nd by Nature in an article entitled "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2HG)".

"The important discovery by Agios and the publication of the Nature article solidifies Agios' leading role in cancer metabolism," Michael Hui, founder and CEO of ChemPartner commented. "ChemPartner has been providing integrated drug discovery research support in the areas of protein science, HTS, enzymology, cell biology, in vivo pharmacology, and DMPK to Agios' innovative R&D programs in the emerging field of cancer metabolism. We congratulate the great achievement by Agios scientists and are also proud of the contribution we made to this partnership. This also demonstrates the quality of scientific work performed at ChemPartner. We look forward to continuing to help Agios advance its drug discovery programs and pipelines."

"The flexibility and expertise of our partners enabled Agios scientists to make this discovery very quickly," said Michael Su, VP Drug Discovery and Interim CSO at Agios Pharmaceuticals. "This new understanding of IDH1 mutants has opened up a new strategy for treating certain forms of cancer. ChemPartner's scientific capabilities will facilitate the continued progress of our drug discovery programs and shorten the time to bring new cancer therapeutics to patients."

About Shanghai ChemPartner

Founded in 2003, Shanghai ChemPartner Company Ltd. (ChemPartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 120 pharmaceutical and biotech companies in the world. ChemPartner currently has a team of over 1,000 scientists including over 90 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies.

Further information is available at http://www.shangpharma.com .

SOURCE Shanghai ChemPartner Co., Ltd.


'/>"/>
SOURCE Shanghai ChemPartner Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. American Scientific Resources Inc. Opens Shanghai Location
2. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
3. UNT Health Science Centers Groundbreaking Research Applied to Protecting Brain After Traumatic Injury
4. Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research
5. Lake Hospital System Receives $60,000 Grant for Groundbreaking Music Therapy Study
6. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
7. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
8. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
9. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
10. For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain
11. New FDA Approved Breast Cancer Screening Tool
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016   Click here for supplemental information ... DPLO), the nation,s largest independent specialty pharmacy, announced ... to acquire Valley Campus Pharmacy, Inc., doing business ... specialty pharmacy that provides individualized patient care, based ... In 2015, TNH generated approximately $400 million in ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... Research and Markets has announced ... Market 2016-2020" report to their offering. ... The global plastic surgery products market is expected to ... 2016-2020. , ,The growing adoption of laser in aesthetics ... the market. Lasers are used to treat a broad ...
Breaking Medicine Technology:
(Date:4/28/2016)... BROOKLINE, MA (PRWEB) , ... April 28, 2016 , ... ... his revolutionary work in the emerging field of biomechatronics, technology that marries human physiology ... the MIT Media Lab. He is also the Founder of BionX , a ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Management solutions, announces today the availability of its latest software release, NetZoomDC ... capacity management and optimization, providing new analytical capabilities that assess complex capacity ...
(Date:4/28/2016)... ... 28, 2016 , ... One way to ignore solid evidence is to dismiss ... we toss the baby out with the bathwater when we ignore all studies because ... studies and otherwise making better use of education policy research. , “When readers heed ...
(Date:4/28/2016)... ... April 28, 2016 , ... USA Medical Card reminds us that May is National ... stroke is the fourth leading cause of death in the United States; someone has one ... quarter of them in individuals under 65 years old. A stroke is when blood ...
(Date:4/28/2016)... ... April 28, 2016 , ... Anzu®, ... announced a new Residency Education & Collaboration Platform for hospitals and medical ... and a host of collaboration tools designed to improve patient outcomes through ...
Breaking Medicine News(10 mins):